Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05667298 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Organ-Preserving Endoscopic Resection & Adjuvant RADIO-immuno-chemotherapy for Esophageal Cancer

Study acronym: OPERARADIO
StatusActive, Not Recruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date changed from estimate of Jul 1, 2025 to Jun 20, 2025v4
  2. Primary completion date: Jun 1, 2024 to Jul 1, 2025v3 Show 4 more changesShow less
    • Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 10 to confirmed 11
    • Study completion date: Jun 1, 2026 to Jul 1, 2029
    • Site details revised
  3. Trial status: Not Yet Recruiting to Recruitingv2 Show 4 more changesShow less
    • Study sites: 0 to 1
    • Start date changed from estimate of Jan 1, 2023 to Mar 1, 2023
    • Eligibility criteria shortened, about 19 words
    • Study description revised
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The goal of this study is to assess the safety of delivering concurrent adjuvant chemoradiation or immuno-radiation therapy after EMR/ESD in pT1b/T2N0 esophageal cancer patients. The main objectives of the study are: 1. Assess the feasibility of enrolling 10 patients. 2. Assess the safety of delivering concurrent adjuvant chemoradiation or immunoradiation therapy after EMR/ESD in pT1b/T2 esophageal cancer patients
Trial Details
NCT Number NCT05667298
Lead Sponsor University of Manitoba
Collaborators: Manitoba Medical Service Foundation, CancerCare Manitoba, AstraZeneca
Conditions
(from sponsor)		 Esophageal Cancer
Related terms Esophageal Neoplasms
Enrollment 11 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov